New hope for advanced prostate cancer: Two-Drug combo enters human testing
Disease control
Recruiting now
This early-phase study tests a combination of two experimental drugs (HS-20093 and HRS-5041) in men with advanced prostate cancer that has stopped responding to standard hormone therapy. The main goal is to find the safest dose and understand side effects. About 63 participants w…
Phase: PHASE1 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated May 02, 2026 17:01 UTC